Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Primary Purpose
Colitis Ulcerative
Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
SAR443122
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Colitis Ulcerative
Eligibility Criteria
Inclusion Criteria:
- Participants who have clinical evidence of active Ulcerative Colitis [UC] for ≥3 months before screening as confirmed by endoscopy during the screening period and within no more than 10 days prior to randomization.
- Participants must have a minimum disease extent of 15 centimeters from the anal verge.
- Participants are inadequate or non-responders, have shown loss of response, or are intolerant to at least 1 of following approved treatments: amino-salicylate, corticosteroids, immunosuppressants or biologics other than natalizumab (Tysabri®).
- Participants on corticosteroids must be on a stable dose ≥2 weeks prior to screening and during screening period.
- Participants on methotrexate, azathioprine or 6- mercaptopurine must be on treatment for at least 8 weeks prior to screening; and on a stable dose ≥4 weeks prior to screening and during screening period.
- Participants on oral 5-aminosalicylates, mesalamine or sulfasalazine must be on a stable dose for ≥4 weeks prior to screening and during screening period.
- Participants on biologics must have been administered 1) at least 5 half-lives prior to randomization, or 2) participant must have an undetectable level of the biologic in their blood prior to randomization.
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding.
Exclusion Criteria:
- Participants with Crohn's Disease (CD).
- Participants with diagnosis of indeterminate colitis.
- Participants with stool sample positive for culture for aerobic pathogens.
- Participants with prior colectomy or anticipated colectomy during their participation in the study.
- Participants with presence of ileal pouch or ostomy.
- Participants with fulminant disease or toxic megacolon.
- Participants with colonic dysplasia except for adenoma.
- Participants with intestinal failure or short bowel syndrome requiring Total Parenteral Nutrition (TPN).
- Participants with history of recurrent or recent serious infection that has not resolved within 4 weeks prior to randomization.
- Participants presenting with malignancies except history of basal cell carcinoma or in-situ cervical carcinoma.
- Participants with a history or presence of another significant illness that according to the investigator's judgment would adversely affect the subject's ability to participate in this study.
- Participants presenting with fever (≥38°C) or persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the Screening Visit, or history of frequent recurrent infections unacceptable per investigator's judgment
- Participants who were administered any live (attenuated) vaccine within 3 months prior to the randomization Visit.
- Participants with a history of recurrent herpes zoster.
- Participants with uncontrolled diabetes, defined as HbA1c ≥9.0% at the Screening Visit.
- Participants with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated active or latent TB per local guidelines will be excluded from the study unless it is documented by a specialist that the participant has been adequately treated and can now start treatment with the RIPK1 kinase inhibitor.
- Participants presenting with opportunistic infections within six months prior to screening or while receiving anti-TNF treatment in the last 6 months.
- Participants undergoing hemodialysis or peritoneal dialysis.
- Participants with a known history of Human Immunodeficiency Virus (HIV) infection or positive HIV serology at screening.
- Participants with Positive Hepatitis B surface antigen (HBsAg) or positive Hepatitis B core antibody (HBcAb); and/or positive Hepatitis C antibody (HCV) at the Screening Visit. Participants that were treated for HCV and clear the virus documented by HCV RNA by PCR below the limit of quantification can be eligible.
- Positive COVID-19 screening test suspected of COVID-19 infection or known exposure to COVID-19 during the screening period.
- History of COVID-19 infection within 4 weeks prior to Screening; history of mechanical ventilation or extracorporeal membrane oxygenation (ECMO) due to COVID-19 infection within 3 months prior to Screening or with residual significant complications from COVID-19 making it unsafe for the participant to enter this study.
- Participants presenting alcohol or drug dependency within the 2 years prior to the Screening Visit.
- Participants with unexplained, uncontrolled, or untreated thyroid disease or unexplained abnormal serum prolactin levels.
- Participants under cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide or tacrolimus treatment within 4 weeks prior to screening.
- Participants with previous exposure to natalizumab (Tysabri®), JAK (Janus kinase) inhibitors or S1P receptor modulator.
- Participants with previous exposure to RIPK1 inhibitor.
- Participants under antidiarrheals within 2 weeks prior to screening and during screening period.
- Participants under prednisone >25 mg/day (or equivalent).
- Participants under budesonide >9 mg/day.
- Participants who received intravenous corticosteroids within 2 weeks prior to screening or during screening.
- Participants who were rectally administered topical 5-aminosalicylate or corticosteroids within 4 weeks prior to screening.
- Participants who received therapeutic enema or suppository, other than required for colonoscopy or flexible sigmoidoscopy within 4 weeks prior to screening or during screening.
- Participants who received antibiotics for UC or gastrointestinal infection within 4 weeks prior to screening.
- Participants who have taken other investigational medications within 2 months or 5 half-lives, (whichever is longer) prior to screening.
- Presence of significant laboratory findings at the Screening Visit.
- Note: Other protocol defined inclusion/exclusion criteria may apply.
Sites / Locations
- United Medical Doctors-Site Number:8400005Recruiting
- Gastrointestinal Bioscience-Site Number:8400006Recruiting
- Las Vegas Medical Research-Site Number:8400004Recruiting
- Onsite Clinical Solutions-Site Number:8400003Recruiting
- Investigational Site Number :0320001Recruiting
- Investigational Site Number :1520001Recruiting
- Investigational Site Number :8260003Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
SAR443122 level 1
SAR443122 level 2
SAR443122 level 3
Placebo
Arm Description
Dose level 1
Dose level 2
Dose level 3
Matching Placebo
Outcomes
Primary Outcome Measures
Proportion of participants who achieve clinical remission at Week 12 by modified Mayo Score (mMS)
The Mayo score (full MS) is a composite instrument that consists of patient reported stool frequency and rectal bleeding, endoscopy-derived measures and physician-reported assessment (PGA). The modified Mayo score is calculated omitting PGA. And an endoscopy score of 1 with no friability.
Secondary Outcome Measures
Proportion of participants who achieve endoscopic improvement at Week 12
Proportion of participants who achieve clinical response at Week 12 by mMS
Proportion of participants who achieve clinical remission at Week 12 by full Mayo Score (MS)
Proportion of participants who achieve clinical response at Week 12 by MS.
Change from baseline on patient-reported outcome 2 (PRO2) total score (Mayo stool frequency and rectal bleeding subscores) over time
Proportion of participants who achieve histological improvement at Week 12
Proportion of participants who achieve Histologic-endoscopic mucosal improvement (HEMI) at Week 12 defined by achievement of modified Mayo endoscopic improvement and histological improvement
Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 12
Change from baseline in bowel signs and symptoms assessed by Ulcerative Colitis Patient Reported Outcome Signs and Symptoms (UC-PRO/SS) at Week 12
Change from baseline in abdominal signs and symptoms assessed by UC-PRO/SS at Week 12
Pharmacokinetic parameters: maximum concentration [Cmax]
Pharmacokinetic parameters: time to Cmax [tmax]
Pharmacokinetic parameters: area under the curve over the dosing interval [AUC0-tau]
Pharmacokinetic parameters: elimination half-life [t1/2z]
Participants with any Treatment Emergent Adverse Events (TEAEs) during induction and maintenance treatment period
Participants with any TEAEs during open-label treatment period
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05588843
Brief Title
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Official Title
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis
Study Type
Interventional
2. Study Status
Record Verification Date
August 24, 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 25, 2022 (Actual)
Primary Completion Date
June 19, 2025 (Anticipated)
Study Completion Date
April 9, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters.
The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to severe UC. All participants will receive a total of 52 weeks (a 12-week induction treatment phase and a 40-week maintenance phase) of study treatment, except if treatment should be discontinued per investigator's assessment.
At the end of the first 12 weeks of induction treatment, all participants in clinical response or remission will be offered study treatment up to 40 weeks and will continue with the same blinded treatment that was assigned. Participants who do not achieve clinical response or remission at the end of the initial 12 weeks induction treatment will roll over in an open-label treatment arm and will be treated with SAR443122 at the highest tested dose.
In addition, participants from the maintenance treatment that lose clinical efficacy at any time up to V10/Week 40 (Week 28 of maintenance) will be offered to roll over in the open-label treatment arm with SAR443122 at the highest dose.
Detailed Description
Total study duration per participant will be up to 58 weeks, including a screening period of up to 4 weeks, a treatment period up to 52 weeks and a post-treatment follow-up period of 2 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colitis Ulcerative
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
182 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
SAR443122 level 1
Arm Type
Experimental
Arm Description
Dose level 1
Arm Title
SAR443122 level 2
Arm Type
Experimental
Arm Description
Dose level 2
Arm Title
SAR443122 level 3
Arm Type
Experimental
Arm Description
Dose level 3
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching Placebo
Intervention Type
Drug
Intervention Name(s)
SAR443122
Intervention Description
oral capsule
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
oral capsule
Primary Outcome Measure Information:
Title
Proportion of participants who achieve clinical remission at Week 12 by modified Mayo Score (mMS)
Description
The Mayo score (full MS) is a composite instrument that consists of patient reported stool frequency and rectal bleeding, endoscopy-derived measures and physician-reported assessment (PGA). The modified Mayo score is calculated omitting PGA. And an endoscopy score of 1 with no friability.
Time Frame
At Week 12
Secondary Outcome Measure Information:
Title
Proportion of participants who achieve endoscopic improvement at Week 12
Time Frame
At Week 12
Title
Proportion of participants who achieve clinical response at Week 12 by mMS
Time Frame
At Week 12
Title
Proportion of participants who achieve clinical remission at Week 12 by full Mayo Score (MS)
Time Frame
At Week 12
Title
Proportion of participants who achieve clinical response at Week 12 by MS.
Time Frame
At Week 12
Title
Change from baseline on patient-reported outcome 2 (PRO2) total score (Mayo stool frequency and rectal bleeding subscores) over time
Time Frame
From baseline to Week 12
Title
Proportion of participants who achieve histological improvement at Week 12
Time Frame
At Week 12
Title
Proportion of participants who achieve Histologic-endoscopic mucosal improvement (HEMI) at Week 12 defined by achievement of modified Mayo endoscopic improvement and histological improvement
Time Frame
At Week 12
Title
Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 12
Time Frame
At Week 12
Title
Change from baseline in bowel signs and symptoms assessed by Ulcerative Colitis Patient Reported Outcome Signs and Symptoms (UC-PRO/SS) at Week 12
Time Frame
At Week 12
Title
Change from baseline in abdominal signs and symptoms assessed by UC-PRO/SS at Week 12
Time Frame
At Week 12
Title
Pharmacokinetic parameters: maximum concentration [Cmax]
Time Frame
Until Week 52
Title
Pharmacokinetic parameters: time to Cmax [tmax]
Time Frame
Until Week 52
Title
Pharmacokinetic parameters: area under the curve over the dosing interval [AUC0-tau]
Time Frame
Until Week 52
Title
Pharmacokinetic parameters: elimination half-life [t1/2z]
Time Frame
Until Week 52
Title
Participants with any Treatment Emergent Adverse Events (TEAEs) during induction and maintenance treatment period
Time Frame
Until Week 52
Title
Participants with any TEAEs during open-label treatment period
Time Frame
Up to Week 52
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participants who have clinical evidence of active Ulcerative Colitis [UC] for ≥3 months before screening as confirmed by endoscopy during the screening period and within no more than 10 days prior to randomization.
Participants must have a minimum disease extent of 15 centimeters from the anal verge.
Participants are inadequate or non-responders, have shown loss of response, or are intolerant to at least 1 of following approved treatments: amino-salicylate, corticosteroids, immunosuppressants or biologics other than natalizumab (Tysabri®).
Participants on corticosteroids must be on a stable dose ≥2 weeks prior to screening and during screening period.
Participants on methotrexate, azathioprine or 6- mercaptopurine must be on treatment for at least 8 weeks prior to screening; and on a stable dose ≥4 weeks prior to screening and during screening period.
Participants on oral 5-aminosalicylates, mesalamine or sulfasalazine must be on a stable dose for ≥4 weeks prior to screening and during screening period.
Participants on biologics must have been administered 1) at least 5 half-lives prior to randomization, or 2) participant must have an undetectable level of the biologic in their blood prior to randomization.
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding.
Exclusion Criteria:
Participants with Crohn's Disease (CD).
Participants with diagnosis of indeterminate colitis.
Participants with stool sample positive for culture for aerobic pathogens.
Participants with prior colectomy or anticipated colectomy during their participation in the study.
Participants with presence of ileal pouch or ostomy.
Participants with fulminant disease or toxic megacolon.
Participants with colonic dysplasia except for adenoma.
Participants with intestinal failure or short bowel syndrome requiring Total Parenteral Nutrition (TPN).
Participants with history of recurrent or recent serious infection that has not resolved within 4 weeks prior to randomization.
Participants presenting with malignancies except history of basal cell carcinoma or in-situ cervical carcinoma.
Participants with a history or presence of another significant illness that according to the investigator's judgment would adversely affect the subject's ability to participate in this study.
Participants presenting with fever (≥38°C) or persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the Screening Visit, or history of frequent recurrent infections unacceptable per investigator's judgment
Participants who were administered any live (attenuated) vaccine within 3 months prior to the randomization Visit.
Participants with a history of recurrent herpes zoster.
Participants with uncontrolled diabetes, defined as HbA1c ≥9.0% at the Screening Visit.
Participants with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated active or latent TB per local guidelines will be excluded from the study unless it is documented by a specialist that the participant has been adequately treated and can now start treatment with the RIPK1 kinase inhibitor.
Participants presenting with opportunistic infections within six months prior to screening or while receiving anti-TNF treatment in the last 6 months.
Participants undergoing hemodialysis or peritoneal dialysis.
Participants with a known history of Human Immunodeficiency Virus (HIV) infection or positive HIV serology at screening.
Participants with Positive Hepatitis B surface antigen (HBsAg) or positive Hepatitis B core antibody (HBcAb); and/or positive Hepatitis C antibody (HCV) at the Screening Visit. Participants that were treated for HCV and clear the virus documented by HCV RNA by PCR below the limit of quantification can be eligible.
Positive COVID-19 screening test suspected of COVID-19 infection or known exposure to COVID-19 during the screening period.
History of COVID-19 infection within 4 weeks prior to Screening; history of mechanical ventilation or extracorporeal membrane oxygenation (ECMO) due to COVID-19 infection within 3 months prior to Screening or with residual significant complications from COVID-19 making it unsafe for the participant to enter this study.
Participants presenting alcohol or drug dependency within the 2 years prior to the Screening Visit.
Participants with unexplained, uncontrolled, or untreated thyroid disease or unexplained abnormal serum prolactin levels.
Participants under cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide or tacrolimus treatment within 4 weeks prior to screening.
Participants with previous exposure to natalizumab (Tysabri®), JAK (Janus kinase) inhibitors or S1P receptor modulator.
Participants with previous exposure to RIPK1 inhibitor.
Participants under antidiarrheals within 2 weeks prior to screening and during screening period.
Participants under prednisone >25 mg/day (or equivalent).
Participants under budesonide >9 mg/day.
Participants who received intravenous corticosteroids within 2 weeks prior to screening or during screening.
Participants who were rectally administered topical 5-aminosalicylate or corticosteroids within 4 weeks prior to screening.
Participants who received therapeutic enema or suppository, other than required for colonoscopy or flexible sigmoidoscopy within 4 weeks prior to screening or during screening.
Participants who received antibiotics for UC or gastrointestinal infection within 4 weeks prior to screening.
Participants who have taken other investigational medications within 2 months or 5 half-lives, (whichever is longer) prior to screening.
Presence of significant laboratory findings at the Screening Visit.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Trial Transparency email recommended (Toll free number for US & Canada)
Phone
800-633-1610
Ext
option 6
Email
Contact-US@sanofi.com
Facility Information:
Facility Name
United Medical Doctors-Site Number:8400005
City
Los Alamitos
State/Province
California
ZIP/Postal Code
90720
Country
United States
Individual Site Status
Recruiting
Facility Name
Gastrointestinal Bioscience-Site Number:8400006
City
Los Angeles
State/Province
California
ZIP/Postal Code
90067
Country
United States
Individual Site Status
Recruiting
Facility Name
Las Vegas Medical Research-Site Number:8400004
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89113
Country
United States
Individual Site Status
Recruiting
Facility Name
Onsite Clinical Solutions-Site Number:8400003
City
Salisbury
State/Province
North Carolina
ZIP/Postal Code
28144
Country
United States
Individual Site Status
Recruiting
Facility Name
Investigational Site Number :0320001
City
San Miguel de Tucuman
ZIP/Postal Code
T4000AXL
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Investigational Site Number :1520001
City
Santiago
State/Province
Reg Metropolitana De Santiago
ZIP/Postal Code
7500010
Country
Chile
Individual Site Status
Recruiting
Facility Name
Investigational Site Number :8260003
City
Warrington
ZIP/Postal Code
WA5 1QG
Country
United Kingdom
Individual Site Status
Recruiting
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Learn more about this trial
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
We'll reach out to this number within 24 hrs